Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)

• Company Description    Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. Number of Employees: 275

• Price / Volume Information    Yesterday's Closing Price: $246.54 Daily Weekly Monthly 20 Day Moving Average: 277,539 shares Shares Outstanding: 29.00 (millions) Market Capitalization: $7,149.05 (millions) Beta: 0.46 52 Week High: $256.00 52 Week Low: $122.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.07% 11.26% 12 Week 30.61% 28.50% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2100 WHARTON STREET SUITE 701 - PITTSBURGH,PA 15203 USA ph: 412-586-5830 fax: - investors@krystalbio.com http://www.krystalbio.com

• General Corporate Information    Officers Krish S. Krishnan - Chief Executive Officer and President Suma M. Krishnan - President Kathryn A. Romano - Chief Accounting Officer Daniel S. Janney - Director Dino A. Rossi - Director Peer Information Krystal Biotech, Inc. (CORR.) Krystal Biotech, Inc. (RSPI) Krystal Biotech, Inc. (CGXP) Krystal Biotech, Inc. (BGEN) Krystal Biotech, Inc. (GTBP) Krystal Biotech, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501147102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/18/26 Share - Related Items Shares Outstanding: 29.00 Most Recent Split Date: (:1) Beta: 0.46 Market Capitalization: $7,149.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $1.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $8.34 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/18/26

• Fundamental Ratios P/E Current FY Estimate: 29.56 Trailing 12 Months: 36.96 PEG Ratio: - Price Ratios Price/Book: 6.28 Price/Cash Flow: 53.16 Price / Sales: 19.16 EPS Growth vs. Year Ago Period: 192.31% vs. Previous Quarter: 106.20% Sales Growth vs. Year Ago Period: 16.65% vs. Previous Quarter: 1.83% ROE 12/31/25 - - 09/30/25 - 19.36 06/30/25 - 15.21 ROA 12/31/25 - - 09/30/25 - 17.65 06/30/25 - 13.81 Current Ratio 12/31/25 - - 09/30/25 - 10.14 06/30/25 - 9.68 Quick Ratio 12/31/25 - - 09/30/25 - 9.73 06/30/25 - 9.33 Operating Margin 12/31/25 - - 09/30/25 - 53.30 06/30/25 - 40.85 Net Margin 12/31/25 - - 09/30/25 - 53.30 06/30/25 - 40.85 Pre-Tax Margin 12/31/25 - - 09/30/25 - 50.10 06/30/25 - 46.98 Book Value 12/31/25 - - 09/30/25 - 39.24 06/30/25 - 35.96 Inventory Turnover 12/31/25 - - 09/30/25 - 0.68 06/30/25 - 0.90 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©